WCCT Global Announces Patient Screening Capabilities in Langhorne, PA Location
COSTA MESA, Calif., April 21, 2015/PRNewswire-iReach/—WCCT Global, a contract research organization (CRO) headquartered in Orange County, CA, is expanding its contract research services to its Langhorne, Pennsylvania location, to better serve Sponsors looking for a CRO that can manage multiple aspects of the clinical trial process anywhere in the country. The facility will now be capable of screening patients for clinical trials. Originally, The east coast HQ for WCCT’s PMO, Data Management, Bio-Stats, Medical Writing and Business Development teams, has been built out to be a fully functional patient screening facility, with all the screening capabilities of the company’s Southern California clinical pharmacology units and other facilities nation-wide.
The expansion marks a shift for the CRO as a whole, as it begins implementing more targeted, regionalized approach throughout the country, offering a more localized version of its contract research services. The company hopes to be able not only to respond to global and national needs for clinical research, but be able to better respond to the clinical research needs of individual communities across the United States. The additional facility will likely contribute to the company’s clinical trial patient recruitment services, as it can now see patients directly in the Pennsylvania area.
WCCT has already had a presence outside of the Southern California region for many years, but the decision to expand the capabilities of one of its own major, East coast facilities signals a growth for the company in terms of the availability of its contract research services and its dedication to clinical research anywhere in the country. While there are many aspects of clinical research that can be conducted remotely, patient screening is an important, in-person task that can now be completed directly by WCCT Global on that side of the U.S.
Lee Barsky, WCCT Global’s Vice President of Global Clinical Development, has this to say about the Langhorne site’s new patient screening capabilities: “This is an excellent step for the company as we continue to grow and re-evaluate our most important contract research services on a larger scale, identifying ways WCCT Global can best serve the pharmaceutical, biotech, and medical device industries. I’m very excited to see what comes as a result of this addition.”